AstraZeneca

AstraZeneca

AstraZenecaAstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit www.astrazeneca.com.

AstraZeneca RSS Channel

Filters
List of articles in category AstraZeneca
Title Published Date
ONGLYZA (saxagliptin) Receives Marketing Authorisation in Europe for the Treatment of Type 2 Diabete 06 October 2009
Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks 31 August 2009
IRESSA (Gefitinib) Receives Marketing Authorisation in Europe 02 July 2009
ONGLYZA (saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes 26 June 2009
AstraZeneca and Abbott Extend Relationship to Include Co-Promotion of Trilipix 05 June 2009
AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration 02 June 2009
AstraZeneca Announces Top Line Results From Pivotal Phase III Study for BRILINTA 12 May 2009
IRESSA (Gefitinib) Recommended for Approval for the Treatment of Non-Small Cell Lung Cancer in Europe 28 April 2009
AstraZeneca PLC Fourth Quarter and Full Year Results 2008 29 January 2009
MedImmune's Application for Intranasal Vaccine to Prevent Seasonal Influenza 09 January 2009
AstraZeneca and Bristol-Myers Squibb Announce Expansion of Worldwide Collaboration 09 December 2008
AstraZeneca to divest Nordic over-the-counter portfolio 22 November 2008
AstraZeneca PLC Third Quarter and Nine Months Results 2008 30 October 2008
AstraZeneca PLC Third Quarter and Nine Months Results 2008 30 October 2008